Involvement of iron in MPP+ toxicity in substantia nigra: Protection by desferrioxamine

Brain Research

Volumn 773, Issue 1-2, 1997, Pages 76-81

  Matarredona, Esperanza R ^a   Santiago, Marti ^a   Cano, Josefina ^a   MacHado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

1 Methyl 4 phenylpyridinium; Dopamine release; Iron chelator; Microdialysis; Rat; Substantia nigra

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; DEFEROXAMINE; IRON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; IRON CHELATION; MALE; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; DEFEROXAMINE; DOPAMINE; FERRIC COMPOUNDS; MALE; MICRODIALYSIS; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA;

EID: 0030726721     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(97)00911-6     Document Type: Article

References (41)

1. + induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 15:1993;181-186.
2. Akenaya Y., Takahashi M., Hatanaka H. Involvement of free-radicals in MPP neurotoxicity against rat dopaminergic-neurons in culture. Neurosci. Lett. 193:1995;53-56.
3. Ambani L.M., Van Woert M.H., Murphy S. Brain peroxidase and catalase in Parkinon's disease. Arch. Neurol. 32:1975;S56-S68.
4. + toxicity in rat striatal slices - relationship between nonselective effects and free-radical production. Neurochem. Res. 21:1996;73-78.
5. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron-melanin interaction and lipid peroxidation: implication for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
6. Boveris A., Chance B. The mitochondrial generation of hydrogen peroxide. Biochem. J. 134:1973;707-716.
7. Chacon J.N., Chedekel M.R., Land E.J., Truscott T.G. Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to the 1-methyl-4-phenylpyridinium ion. Biochem. Biophys. Res. Commun. 144:1987;957-964.
8. Chiba K., Trevor A., Castagnoli N. Jr. Metabolism of the neurotoxic terthiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:1984;574-578.
9. Chiueh C.C., Huang S.J., Murphy D.L. Enhanced hydroxyl radical generation by 2′-methyl analogue of MPTP: Suppression by clorgyline and deprenyl. Synapse. 11:1992;346-348.
10. Cleeter M.W.J., Cooper J.M., Shapira A.H.V. Irreversible inhibition of mitochodrial complex I by 1-methyl-4-phenylpyridinium: Evidence for free radical involvement. J. Neurochem. 58:1992;786-789.
11. Dexter D.T., Wells F.R., Agid F., Agid Y., Lees A.J., Jenner P., Marsden C.D. Increased nigral iron content in postmorten parkinsonian brain. Lancet. 2:1987;1219-1220.
12. Drayer B.P., Olanow W., Burger P., Johnson G.A., Herfkens R., Riederer P. Parkinson plus syndrome: diagnosis using high-field MR imaging of brain iron. Radiology. 159:1986;493-498.
13. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative disease? J. Neurochem. 63:1994;793-807.
14. Halliwell B., Gutteridge J.M.C. Oxigen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219:1984;1-14.
15. +) induces NADH dependent superoxide formation, and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170:1990;1049-1055.
16. +) induces oxidative stress in rodent. Life Sci. 38:1986;743-749.
17. Kish S.J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58:1985;343-346.
18. Langston J.W., Forno L.S., Rebert C.S., Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res. 292:1984;390-394.
19. R.B. Lauffer, Iron and Human diseases, CRC Press, Boca Raton, Florida, 1992.
20. Minotti G., Aust S.D. The requirement for iron III in the initiation of lipid peroxidation by iron II and hydrogen peroxidase. J. Biol. Chem. 262:1987;1098-1104.
21. + on the release of serotonin and 5-hydroxyindoleacetic acid from rat striatum in vivo. Eur. J. Pharmacol. 166:1989;49-55.
22. Monteiro H.P., Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38:1989;4177-4182.
23. G. Paxinos, C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
24. Perry T.L., Godin D.U., Hansen S. Parkinson's disease: a disorder due to nigra glutathione deficiency? Neurosci. Lett. 33:1982;305-310.
25. Qi Y., Jamindar T.M., Dawson G. Hypoxia alters homeostasis and induces ferritin synthesis in oligodendrocites. J. Neurochem. 64:1995;2458-2464.
26. Riederer P., Youdim M.B.H. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J. Neurochem. 46:1986;1359-1365.
27. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
28. +. Eur. J. Pharmacol. 126:1986;345-346.
29. Rollema H., De Vries J.B., Damsma G., Westerink B.H.C., Kranenborg G.L., Kuhr W.G., Horn A.S. The use of in vivo dialysis of dopamine, acetylcholine, aminoacids and lactic acid in studies on the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology. 49:1988;503-511.
30. Rutledge J.N., Hilal S.K., Silver A.J., Defendin R., Fahn S. Study of movement disorders and brain iron by MR. Am. J. Roentgenol. 149:1987;365-379.
31. +-induced cell injury in the striatum of rats. Br. J. Pharmacol. 111:1994;837-842.
32. + on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis. Brain Res. 538:1991;226-230.
33. Santiago M., Westerink B.H.C. Characterization of the in vivo release of dopamine as recorded by different types of intracerebral microdialysis probes. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;407-414.
34. Santiago M., Westerink B.H.C., Rollema H. Responsiveness of striatal dopamine release in awake animals after chronic 1-methyl-4-phenylpyridinium ion-induced lesions of the substantia nigra. J. Neurochem. 56:1991;1336-1342.
35. Singer T.P., Trevor A.J., Castagnoli N. Jr. Biochemistry of the neurotoxic action of MPTP. Trends Biochem. Sci. 12:1987;266-270.
36. +) reductive activation by NADPH cytochrome P-450 reductase. Biochem. Biophys. Res. Commun. 135:1986;583-588.
37. + administration to rat brain by in-vivo microdialysis - a model of oxidative stress. FASEB J. 9:1995;A665-A665.
38. Stohns, Bagchi Oxidative mechanisms in the toxicity of metal ions. Free Radic. Biol. Med. 18:1995;321-336.
39. Westerink B.H.C., Damsma G., Rollema H., de Vries J.B., Horn A.S. Scope and limitations of in vivo brain dialysis: a comparison of its applications to various neurotransmitter systems. Life Sci. 41:1987;1763-1776.
40. M.B.H. Youdim, D. Ben-Shachar, G. Eshel, J.P.M. Finberg, P. Riederer, The neurotoxicity of iron and nitric oxide: relevance to the etiology of Parkinson's disease, in: H. Narabayashi, T. Nagatsu, N. Yanagisawa, Y. Mizuno (Eds.), Advances in Neurology, vol. 60, Raven Press, New York, 1993, pp. 259-266.
41. Yu B.P. Cellular defences against damage from reactive oxygen species. Physiol. Rev. 74:1994;139-162.